FDA approves Prevymis to prevent CMV among stem cell transplant patients
from Clinical Oncology News
The FDA approved letermovir for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). Letermovir is a member of a new class of nonnucleoside CMV inhibitors and inhibits viral replication by specifically targeting the viral terminase complex. Cross-resistance is not likely with drugs outside of this class.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063